#DYK: In our 2Q earnings release, we announced that we have dosed the 1st patients evaluating ELVN-002 in combination with trastuzumab +/- chemo and in combination with ado-trastuzumab emtansine. Review our 2Q press release here: https://bit.ly/46HtxFH
Enliven Therapeutics
Biotechnology Research
Discovering and developing next generation precision oncology therapeutics
Über uns
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.
- Website
-
http://www.enliventherapeutics.com
External link for Enliven Therapeutics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Boulder, CO
- Typ
- In Privatbesitz
- Gegründet
- 2019
- Spezialitäten
- Precision Medicine, Small Molecule Targeted Therapies, and Oncology
Standorte
-
Primäre
Wegbeschreibung erhalten
Boulder, CO, US
Employees at Enliven Therapeutics
Aktualisierungen
-
We are happy to share an abstract with updated ELVN-001 Phase 1a data has been accepted for oral presentation at the European Society of Hematology International CML Foundation Conference this September. Learn about the Phase 1a data announced in April: https://bit.ly/3R5Uv37
-
-
Every day, women everywhere are fighting a battle with breast cancer. We are inspired by their stories, which is why we are working hard to develop ELVN-002, a HER2 inhibitor, as a potential treatment for breast cancer. Learn more about ELVN-002 here: https://bit.ly/3xleJ21
-
-
#DYK: We recently announced the first patient was dosed in the Phase 1b arm evaluating ELVN-001 in CML patients who are relapsed, refractory, or intolerant to available TKIs. Learn about our initial proof-of-concept data from the Phase 1a arm here: https://bit.ly/3R5Uv37
-
-
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update: https://bit.ly/46HtxFH
-
-
#DYK: In healthy volunteers, ELVN-001 did not have a significant food effect, and based on preclinical data, it has minimal risk of DDIs. Learn more about ELVN-001 here: https://bit.ly/3R5Uv37
-
-
#DYK: In its initial proof of concept data, ELVN-001 showed activity in post-asciminib patients, including achieving an MR5 in a patient with an emergent asciminib mutation. Learn more about ELVN-001 here: https://bit.ly/3R5Uv37
-
-
#DYK: ELVN-001 was designed to be an attractive option for patients with comorbidities, on concomitant medications, or desiring freedom from stringent administration requirements. Learn about ELVN-001 and its proof of concept data: https://bit.ly/3R5Uv37
-
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Enliven Therapeutics
4 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 90.0M